OriGene Technologies, Inc., a gene-centric life sciences company based in Maryland, completed a $16 million Series B financing, which it will use to continue building its TrueMAB™ collection of monoclonal antibodies. In February 2009, OriGene purchased the assets of Shenzhen P&A Biotech, a company that provides monoclonal antibodies. OriGene said it would use its new China monoclonal antibody production facility to produce several thousand high quality monoclonal antibodies per year. More details...